Exozymes (EXOZ) CSO receives 5,332-share stock award

Rhea-AI Filing Summary

Korman Tyler Paz reported acquisition or exercise transactions in this Form 4 filing.

Exozymes Inc. reported that Chief Scientific Officer Tyler Paz Korman received a stock grant of 5,332 shares of common stock on April 1, 2026, at a value of $8.44 per share. Following this compensation-related award, Korman directly holds a total of 730,623 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Korman Tyler Paz

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	5,332	$8.44	$45K

Holdings After Transaction: COMMON STOCK — 730,623 shares (Direct)

Footnotes (1)

Key Figures

Shares granted: 5,332 shares Grant value per share: $8.44 per share Total shares held after grant: 730,623 shares

3 metrics

Shares granted 5,332 shares Common stock award on April 1, 2026

Grant value per share $8.44 per share Reported value for the 5,332-share award

Total shares held after grant 730,623 shares Direct ownership by Chief Scientific Officer after transaction

Key Terms

Form 4, grant/award acquisition, Chief Scientific Officer

3 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

grant/award acquisition financial

""transaction_action": "grant/award acquisition""

Chief Scientific Officer financial

""officer_title": "Chief Scientific Officer""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Korman Tyler Paz

(Last) (First) (Middle)

C/O 750 ROYAL OAKS DRIVE,

SUITE 106

(Street)

MONROVIA CALIFORNIA 91016

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXOZYMES INC. [ EXOZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	04/01/2026	04/01/2026	A		5,332	A	$8.44	730,623	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Tyler Korman	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did EXOZ report for Chief Scientific Officer Tyler Paz Korman?

EXOZ reported that Chief Scientific Officer Tyler Paz Korman received a grant of 5,332 shares of common stock. The award was recorded at $8.44 per share and is categorized as a grant or other acquisition, not an open-market purchase or sale.

Was the EXOZ insider transaction a stock purchase or a compensation grant?

The EXOZ insider transaction was a compensation-related grant of shares, not an open-market stock purchase. The filing classifies it as a “grant, award, or other acquisition,” indicating the shares were awarded by the company rather than bought on the market.

How many EXOZ shares does the Chief Scientific Officer hold after this grant?

After receiving the 5,332-share grant, the Chief Scientific Officer directly holds 730,623 shares of EXOZ common stock. This total includes the newly awarded shares and reflects his direct ownership position as reported in the Form 4 filing.

What was the reported value per share for the EXOZ stock grant?

The reported value per share for the EXOZ stock grant was $8.44. This price is used in the Form 4 to indicate the fair value of the 5,332 common shares awarded to the Chief Scientific Officer as part of his compensation package.

Does the EXOZ Form 4 show any stock sales or dispositions by the insider?

The EXOZ Form 4 does not show any stock sales or dispositions by the insider. It reports only one transaction: an acquisition of 5,332 common shares classified as a grant or award, leaving the insider’s net buy-sell activity neutral for this filing.